Bergamonte® supports liver and metabolic wellness through research involving liver biomarkers, lipid and glucose metabolism, oxidative balance, and cellular processes involved in maintaining normal liver function.
Because the liver is deeply involved in lipid processing, glucose metabolism, and energy regulation, Bergamonte® is particularly well suited to liver-focused formulations. The platform combines human research, mechanistic science, and specialized portfolio options such as Bergacyn® to give product developers multiple ways to build differentiated liver and metabolic-health products.
Human + Mechanistic Research
The science includes clinical biomarkers alongside studies of cellular and metabolic pathways.
Dedicated Liver Portfolio Options
Bergacyn® and Bergacyn® FF expand the Bergamonte® platform specifically for liver-focused formulations.
Cellular Renewal Science
Research explores autophagy, lipophagy, and other processes involved in normal cellular maintenance.
Strong Metabolic Connection
Creates natural formulation overlap with glucose, cholesterol, weight management, and healthy aging.
The liver plays a central role in processing nutrients, regulating glucose and lipids, producing bile, and maintaining normal metabolic homeostasis. Bergamonte® research approaches liver wellness from several directions, combining human biomarkers and imaging-related measurements with mechanistic studies of lipid handling and cellular renewal.
Key Clinical Benefits
Human studies of Bergamot Polyphenolic Fraction have evaluated liver-related outcomes within populations also being assessed for metabolic health. The findings connect liver function with glucose regulation, lipid balance, inflammation, and broader cardiometabolic wellness rather than treating the liver as an isolated system.
Clinical research has included measurements such as ALT, AST, γ-GT, hepatorenal index, and other indicators related to normal liver status. Evaluating several endpoints together provides a more complete picture of the ingredient’s liver-health research than relying on one individual enzyme.
Preclinical bergamot research has examined autophagy and lipophagy, natural cellular processes involved in recycling cellular material and managing lipid droplets. These mechanistic findings complement the human biomarker research and provide additional scientific depth for liver-focused formulations.
Human studies across the Bergamonte® platform have evaluated liver-related biomarkers, noninvasive measures of liver fat, oxidative and inflammatory markers, and metabolic factors associated with hepatic health. Together, the research provides a multidimensional view of healthy liver function within the broader metabolic picture.
A 120-day human study evaluated 38%-standardized BPF in participants with metabolic syndrome and hepatic steatosis. Significant changes were reported across liver enzymes and ultrasound-related measures, including ALT, AST, γ-GT and hepatorenal index, which decreased from 2.8 to 1.5 over the study period.
Why it matters: The study connects circulating liver markers with an objective imaging-related measure.
Why it matters: Direct human research measured a greater change in liver fat versus placebo.
A separate 16-week randomized, double-blind study evaluated bergamot, Cynara cardunculus and their combination in adults with type 2 diabetes and hepatic steatosis. The combined formulation produced the strongest overall response across oxidative and inflammatory markers, including significant increases in antioxidant enzymes and reductions in MDA and TNF-α.
Why it matters: The research adds oxidative and inflammatory context to the liver-health story.
A 2022 clinical analysis evaluated serum uric acid in 94 adults with hepatic steatosis receiving the bergamot-cardoon-fiber formulation or placebo. The active group showed a more favorable response, with the largest change observed among participants who began the study with the highest serum uric acid levels; in that subgroup, the adjusted reduction was approximately 7.8%.
Why it matters: Adds another metabolic endpoint to the clinical liver-health evidence.
Results reflect the specific formulations, doses, populations and durations evaluated. The 120-day BPF protocol also included oleuropein and ascorbic acid, while the Bergacyn® studies evaluated bergamot + Cynara cardunculus + bergamot fiber formulations. Outcomes should not be attributed interchangeably across individual Bergamonte® ingredients.
The liver is one of the body’s primary metabolic organs, helping process nutrients, regulate glucose and lipids, produce bile, and manage compounds the body needs to transform or eliminate. Because of this central role, liver wellness is closely intertwined with cholesterol, blood sugar, body composition, and overall cardiometabolic health.
That connection creates an especially strong formulation opportunity for the Bergamonte® platform. In addition to bergamot polyphenol research, dedicated ingredients such as Bergacyn® and Bergacyn® FF expand the portfolio into more targeted liver-focused applications combining Calabrian bergamot with wild cardoon and, in selected formats, bergamot fiber.
The Bergamonte® portfolio offers dedicated liver-focused options, including patented Bergacyn® formulations supported by targeted human research and complementary mechanistic science.
The liver-health portfolio includes both concentrated BPF® research and a specialized bergamot + wild cardoon + bergamot-fiber platform developed around liver and metabolic physiology. Ingredient selection can therefore follow either a broader BPF® approach or a formulation designed specifically around the Bergacyn® clinical architecture.
let’s get started
Discuss your formulation goals, intended positioning, research needs, and product-development opportunities with the HP Ingredients team.
Schedule Now
Evaluate Bergamonte® for your next product concept with a sample for formulation, compatibility, and product-development testing.
Request Now
Ready to explore how Bergamonte® can support your product pipeline? Contact HP Ingredients for samples, technical documentation, clinical research, formulation guidance, and next-step support.
Contact Us